AMAG’s Turnaround Plans Hit A Snag With Feraheme CRL
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA declined to approve the I.V. iron in a broad patient population and requested another clinical trial to further evaluate safety. The decision gives rival Daiichi more time to penetrate the market with its I.V. iron Injectafer.